VEGFA and glioblastoma: For instance, it has been shown that OCM-1 (a cell line used in the present study) produces high levels of notch signalling intermediates, whereas Mel290 expresses low levels [55].Moreover, it has been demonstrated in bladder carcinoma and glioblastoma that high DII4/Notch signalling may confer resistance to anti-VEGF therapies, thus offering a potential explanation for the aforementioned discrepancy [56, 57].